Aventiv Research | Phoenix-Mesa, AZ

Research site

(Unclaimed)

Location

612 W Baseline Road, Mesa, Arizona, United States of America

Site insights

Top conditions

Top treatments

Empagliflozin

Obinutuzumab

DM199

Reloxaliase

KBP-5074

BI 690517

LY3502970

Bardoxolone Methyl

Orforglipron

Tirzepatide

Parent organization

This site is a part of Aventiv Research

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 17 total trials

A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy (MAJESTY)

This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics (PK) of obinutuzumab compared with tacrolimus in participants w...

Active, not recruiting

Primary Membranous Nephropathy

Drug: Tacrolimus

Drug: Methylprednisolone

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Active, not recruiting

Chronic Kidney Disease

Overweight

Drug: Orforglipron

Drug: Insulin Glargine

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO)

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting

Overweight

Obesity

Drug: Placebo

Drug: Tirzepatide

A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults

The purpose of this clinical study is to learn about the safety, extent of the side effects (reaction to vaccine), and immune response (your immune s...

Active, not recruiting

Shingles

Human

Biological: Selected Vaccine Candidate group (Dose level, Schedule)

Biological: Shingrix - SSB

ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with...

Enrolling

Chronic Kidney Disease

Inflammation

Drug: Placebo (Ziltivekimab B)

Drug: Placebo (Ziltivekimab C)